ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1863

Resetting the Naming Speed Clock with Methylphenidate (Ritalin)

Robert S. Katz and Frank Leavitt, Rush University Medical Center, Chicago, IL

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Fibromyalgia and medication

  • Tweet
  • Email
  • Print
Session Information

Title: Fibromyalgia and Soft Tissue Disorders

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Abnormalities in naming speed are an unappreciated feature of cognitive dysfunction in fibromyalgia (FMS).  Approximately 50% of FMS patients with memory problems name words at a rate that is 203 milliseconds slower than the norm.  The connection between naming speed and memory loss in FMS is unclear.  Stimulant medications like methylphenidate have been known to influence naming speed and could provide clues to the relationship between cognitive functioning and naming speed.   The purpose of this paper is to determine if faster naming speed is connected to a positive change in cognitive functioning. 

Methods: A word naming speed measure (Stroop Color and Word Test) and a measure of cognitive functioning (Mental Clutter Scale:MCS) were administered to 15 patients with FMS, before receiving methylphenidate  and post methylphenidate.  The FMS patients were female, met 2010 ACR criteria for FMS and had memory problems. Methylphenidate dosage was clinically determined and ranged from 10 to 30 mg.  The median methylphenidate usage at retesting was 30 days. Naming speed was determined by the number of words named in a 45 second time period.

Results: The mean age of the FMS sample was 46.3±11.6  years  with 14.1±2.1 years of education.  Twelve of 15 FMS patients showed a significant reduction in time needed to name words post methylphenidate.  Pre- methylphenidate, they read 77.4 words in 45 seconds or 605 milliseconds (45/77.4) per word.  Post methylphenidate, they read 93 words in 45 seconds or 498 milliseconds (45/93) per word.  This represents a 107 millisecond benefit from methylphenidate. The normative sample reads 108 words in 45 sec. or 417 msec.  per word.   Post methylphenidate changes on the Cognition and Mental Clarity subscales of the MCS are shown in Table 1.  FMS patients showed a 17 point improvement with methylphenidate on Cognition, and a 19 point improvement on mental clarity.   Both  changes were significant at p<0.01.   

 Conclusion: Methylphenidate appears to have short term benefits for naming speed and cognitive functioning in fibromyalgia.  It quickly allows patients with FMS to operate at a more normal pace in naming words  and broadly improves cognitive functioning.  Elimination of the 107 millisecond time lag is thought to reset the neural clock in FMS so that word information is back in sync with other streams of neural information. The benefits of  methylphenidate clearly show  a connection between faster naming speed and improved cognition, however, it remains to  be determined  whether  positive  changes in cognition  are  brought on by  faster  neural transmission that likely underlies faster naming speed.    

  Table 1.   Pre- methylphenidate and Post- methylphenidate Scores on the Cognition and Mental Clarity Subscales of the Mental Clutter Scale.

___________________________________________________________________________

                            Pre- methylphenidate                     Post- methylphenidate      

 Cognition                 52.8±15.6                                          35.1±11.3**a

 Mental  Clarity          48.1 ± 16.5                                        29.2±13.6**

 __________________________________________________________________________

**p<0.01

aLower scores represent improved performance


Disclosure:

R. S. Katz,
None;

F. Leavitt,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/resetting-the-naming-speed-clock-with-methylphenidate-ritalin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology